<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765011</url>
  </required_header>
  <id_info>
    <org_study_id>TTCC-2007-02</org_study_id>
    <nct_id>NCT00765011</nct_id>
  </id_info>
  <brief_title>TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer</brief_title>
  <official_title>A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of
      Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment
      With TPF Chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being sponsored by a cooperative medical group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific survival</measure>
    <time_frame>Three years after the end of treatment with radiotherapy and cetuximab</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPF plus concomitant treatment with cetuximab and conventional radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grupo B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF, radiotherapy and cetuximab</intervention_name>
    <description>3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>TPF plus radiotherapy and cetuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>H&amp;N surgery</intervention_name>
    <description>Rescue surgery</description>
    <arm_group_label>Grupo B</arm_group_label>
    <other_name>Rescue surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form.

          2. Men or women, age (18 and 70).

          3. ECOG scale:0-1.

          4. Life expectancy superior to 3 months.

          5. Larynx squamous carcinoma histologically demonstrated.

          6. Patients with larynx squamous carcinoma, stage III-IVA, with resectable disease whose
             surgery will imply a total laryngectomy. The T should be a T3, T4A, or a T2 not
             candidate for a partial laryngectomy. In case of T2 of any of both locations it will
             be required a III or IVA stadium.

          7. Patients to be able to receive treatment with TPF followed by normofractionated
             radiotherapy with cetuximab.

          8. Measurable disease (OMS criteria).

          9. Neutrophils superior or equal to 1500/mm3, platelets superior or equal to 150.000/mm3,
             hemoglobin superior or equal to 10 g/dl.

         10. Adequate renal function: creatinin lower or equal to 120 µmol/l (1,4mg/dl)

         11. Adequate hepatic function: bilirubin lower or equal to 1 x UNL, AST and ALT lower or
             equal to 2,5 UNL, alkaline phosphatase lower or equal to 5 UNL.

         12. Seric calcium adjusted to albumine lower or equal to 1,25 UNL.

         13. Adequate nutritional condition: loss of weight &lt;20% with relation to the theoretical
             weight and albumin superior or equal to 35 g/L.

         14. Use of an effective contraceptive method.

        Exclusion Criteria:

          1. Metastatic disease

          2. Surgical treatment, previous radiotherapy and/or chemotherapy for the study disease.

          3. Other tumour locations in H&amp;N that are not larynx.

          4. Other stages that are not III or IVa without metastasis and resectable disease.

          5. The following cases, which will be considered candidates for radical surgery, will not
             be included in the study:

               -  Tumors of the subglottis.

               -  Tumors of glottis or supraglottis with subglottal extension

               -  Tumor that destroys the thyroid cartilage and/or cricoid and it extends to
                  thyroid gland or soft necks's tissues.

               -  Tumor of supraglottis with a superior extension to 1 cm towards the tongue base
                  (the extension will be measured since the vallecula).

          6. Other previous and/or synchronic squamous carcinoma.

          7. Diagnosis of another neoplasia in the last 5 years, excepting carcinoma in situ of
             uterine neck and/or a cutaneous carcinoma basocellular properly treated.

          8. Active infection(at needs endovenous antibiotics), including active tuberculosis and
             diagnosed HIV.

          9. Not controlled hypertension defined as arterial systolic tension superior or equal to
             180 mm Hg and/or diastolic arterial tension superior or equal to 130 mm Hg baseline.

         10. Pregnancy or breastfeeding.

         11. Immunity systemic treatment, chronic and concomitant, or hormonal treatment of the
             cancer.

         12. Other antineoplasic concomitant treatments.

         13. Coronary clinically significant arteriopathy or precedents of myocardial infarction in
             the last 12 months or high risk of not controlled arrhythmia or cardiac not controlled
             insufficiency.

         14. Pulmonary obstructive chronic disease that had needed 3 or more hospitalizations in
             the last 12 months.

         15. Active non controlled peptic ulcer.

         16. Presence of a psychological or medical disease that could prevent to accomplish the
             study by the patient or to grant his/her signature in the informed consent form.

         17. Known drugs abuse (excepting excessive consumption of alcohol).

         18. Known allergic reaction to some of the components of the treatment of the study.

         19. Previous treatment with monoclonal antibodies or other transduction of the sign
             inhibitors or treatment directed against the EGFR.

         20. Any experimental treatment in 30 days before entry in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricard Mesía Nin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Durán i Reynals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José A. García Sáenz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan C Adansa, MD</last_name>
    <phone>+34 923 29 11 00</phone>
    <phone_ext>749</phone_ext>
    <email>unidad_eecc@usal.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Beatriz Cirauqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ricard Mesia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Esther Casado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan J Grau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Yagüe</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mª Angeles Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr.Josep Trueta (ICO Girona)</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio L Irigoyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncogranada</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Ciudad de Jaén</name>
      <address>
        <city>Jaén</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Calde</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José R Mel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Quirón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yolanda escobar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José A García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llátzer</name>
      <address>
        <city>Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mª Belén González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan J Cruz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elvira del Barco Morillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Carlos Adansa Klain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Pastor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Cies</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julio Lambea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Martínez Trufero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttccgrupo.org</url>
    <description>This site would like to expose the activities of the group and at the same time serve as an information and communication tool of this pathology for professionals and patients.</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>February 12, 2011</last_update_submitted>
  <last_update_submitted_qc>February 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Juan Jesús Cruz</name_title>
    <organization>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</organization>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

